Q BioMed Announces Strontium89 Initial Uptake and Momentum in US and Europe
Several International Market Authorisations Expected in Q4 Expanding Access to South and Central America and Asia PR Newswire NEW YORK,
Read more
qbio
Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program
COVID-19 clinical trial planned for Q1 2021 supported by Canadian Government Proof of concept would validate platform for multiple indications
Read more
Q BioMed Announces Strontium89 will be available as of September 2020 through Named Patient Program for Bone Metastases Pain Palliation in EU and Rest of World
PR Newswire NEW YORK, Aug. 11, 2020 NEW YORK, Aug. 11, 2020 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced
Read more
Q BioMed Announces Global Distribution Partnership With Caligor Coghlan Pharma Services for its Non-Opioid Cancer Palliation Drug
Caligor Coghlan Pharma Services to Distribute Strontium89 (Strontium Chloride Injection Sr-89 USP) Outside the United States Agreement opens international markets
Read more
Denis Corin, CEO, of Q BioMed Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com
NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) — SmallCapVoice.com, Inc. (SCV) and Q BioMed Inc. (OTCQB: QBIO) (the “Company”), a
Read more
Q BioMed Inc. Discusses The Commercialization of Its FDA Approved Metastatic Bone Pain Drug with The Stock Day Podcast (QBIO) April 27, 2020
Newsfile Corp.Newsfile Corp Phoenix, Arizona–(Newsfile Corp. – April 27, 2020) – The Stock Day Podcast welcomed Q BioMed Inc. (OTCQB:
Read more
Q BioMed Adds to Leadership Team With Global Head of Regulatory Affairs
Initial focus on global rollout of Strontium89 PR Newswire NEW YORK, March 31, 2020 NEW YORK, March 31, 2020 /PRNewswire/ — Q BioMed
Read more